Grappone Conference Center
70 Constitution Avenue
Concord, NH 03301
ICER will develop a report reviewing the clinical effectiveness and value of abuse-deterrent opioids. The report will be the subject of a July 20, 2017 meeting of the New England CEPAC.
The live webcast is available here: http://www.bizvision.com/webcast/prod/84251Register or Register for the Live Webcast
University of Missouri-St. Louis
1 University Boulevard
St. Louis, MO 63121
ICER will review evidence on the comparative clinical effectiveness and value of certain cognitive and mind-body interventions for chronic low back and neck pain.
The Midwest CEPAC will convene to deliberate on ICER's report on voretigene neparvovec.
The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.
The CTAF Panel will convene to review ICER's report on drug treatments for osteoporosis.
ICER is hosting a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit will include discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.
Process for Public Comment
A Briefing Paper posted on May 10, 2017 (white paper below) informed during the pricing summit. Following the meeting, ICER will produce a Final Meeting Report and Proposed Framework Changes document outlining modifications to its assessment process when applied to treatments for rare conditions. This document will be open for public comment for 60 days. Dates reflected below are tentative and subject to change.
The Midwest CEPAC convened in May 2017 to discuss ICER's report on dupilumab and crisaborole for atopic dermatitis.
The New England CEPAC convened on March 24, 2017 to discuss ICER's report on treatments for rheumatoid arthritis.
The California Technology Assessment Forum convened to discuss ICER's report on treatments for Multiple Sclerosis.
The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on treatments for psoriasis.
The Midwest CEPAC convened in October 2016 to discuss ICER's report on treatments for non-small cell lung cancer.
The New England CEPAC convened to deliberate and vote on evidence presented in ICER's report on obeticholic acid (Intercept Pharmaceuticals, Inc.) for use in PBC and NASH.
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), held a public meeting in June 2016 to discuss the comparative effectiveness and value of diabetes prevention programs.
At its inaugural meeting, the Midwest CEPAC convened to discuss the comparative clinical effectiveness and value of therapies for multiple myeloma.